| Industry | 批发和零售业 | ||||||||||||||||||||||||
| Company Introduction | 上海医药集团股份有限公司是一家致力于医药行业的企业,前身系上海第四制药厂,于1993年始进行股份制改组,其主要产品包括了各类药品及保健品。集团重大资产重组项目获证券时报年度"最佳创新项目",并被评为2010年上海国资"最受市场认可的重组",在证券之星、第一财经以及上海市股份公司联合会共举办的"上海上市公司评选"中荣获"最佳转型奖"。集团还荣获"2010年中国最具投资价值的医药上市公司10强"称号,"中国医药上市公司竞争力50强"榜首,中国医药行业"十大最具影响力企业"之一,"投资者关系管理百强";荣列上海企业100强第19位、上海制造业企业50强第9位、中国企业500强第203位、中国制造业企业500强第99位、中国制药工业百强第3位等。 | ||||||||||||||||||||||||
| Main Business | 药品及保健品的研发、生产和销售；向医药制造商及配药商(例如医院、分销商及零售药店)提供分销、仓储、物流和其他增值医药供应链解决方案及相关服务；以及经营自营及加盟的零售药店网络。 | ||||||||||||||||||||||||
| Legal Representative | 杨秋华 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 钟涛 | ||||||||||||||||||||||||
| Solicitors | 国浩律师（上海）事务所 | ||||||||||||||||||||||||
| Auditors | 普华永道中天会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | +8621-63730908 | ||||||||||||||||||||||||
| Fax No | +8621-63289333 | ||||||||||||||||||||||||
| Website | www.sphchina.com | ||||||||||||||||||||||||
| pharm@sphchina.com；boardoffice@sphchina.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 24/03/1994 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 1.020 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.410 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 18.500 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 40.667B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |